About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Memorial Sloan Kettering Cancer Center
https://www.mskcc.org/healthcare-professionals
Refer a Patient to MSKCC:
mskcc.org/refer
COVID-19
Myeloma
Leukemia
Lymphoma
Hematologic Transplantation and Malignancies
Breast
Lung
Gastrointestinal
Genitourinary
Gynecologic
Skin
Head and Neck
Brain
General Oncology
Palliative Care
Events
MPN
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Q&A on EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC
By
GRACE
FEATURING
Helena Yu
By
GRACE
FEATURING
Helena Yu
24 views
July 22, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Lung
14:26
Memorial Sloan Kettering Cancer Center
Radiation for Unresectable NSCLC: Where Are We Now and Where Are We …
Feat.
D. Gomez
26:21
Memorial Sloan Kettering Cancer Center
NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…
Feat.
M. Hwang
14:52
Memorial Sloan Kettering Cancer Center
Advances in Resectable NSCLC
Feat.
K. Gray
09:38
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "CDC7 Inhibition Constrains Lineage Plastic…
Feat.
A. Quintanal-Villalonga
06:04
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Durable Efficacy of Zenocutuzumab, a HER2 …
Feat.
A. Schram
14:02
Insights from 2023 WCLC
WCLC 2023 Insights: "MSI and MMR-D Define a Distinct Subset of …
Feat.
S. Yang
10:18
i3 Health
Additional Advances in Squamous NSCLC Research and Clinical Trials
Feat.
M. Kris
08:03
i3 Health
New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertio…
Feat.
H. Yu,
M. Arcila
10:16
Memorial Sloan Kettering Cancer Center
2021 ASCO Updates on KEYLYNK-013 Study for Newly Diagnosed LS-SCLC: …
Feat.
A. Rimner
05:59
Memorial Sloan Kettering Cancer Center
2021 ASCO Updates on METex14 Skipping mNSCLC: ctDNA Dynamics & R…
Feat.
P. Paik
20:40
Memorial Sloan Kettering Cancer Center
Can TTFields with Chemotherapy Improve Clinical Outcome in the First…
Feat.
C. Simone II
17:52
Memorial Sloan Kettering Cancer Center
Malignant Pleural Mesothelioma: What Do Clinical Trials Suggest on A…
Feat.
M. Zauderer
16:53
Memorial Sloan Kettering Cancer Center
Should We Combine EGFR TKIs With Upfront Radiation Therapy in EGFR+ …
Feat.
K. Beal
21:24
GRACE
Is There a Role for IO in EGFR+ Metastatic Lung Cancer?
Feat.
H. Yu
19:58
Beacon Medical Interchange
Current Practice & Challenges in Execution of Genomic Testing in…
Feat.
J. West,
G. Riely
28:12
Beacon Medical Interchange
Should Local Ablation Therapy in Oligometastatic or Oligoprogressing…
Feat.
J. West,
G. Riely
23:26
CancerGRACE
EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC
Feat.
H. Yu
09:30
GRACE
Q&A on EGFR Initial Treatment and Acquired Resistance in Advance…
Feat.
H. Yu
07:39
Nebraska Oncology Society
ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III T…
Feat.
G. Riely
16:08
Nebraska Oncology Society
Stage IV NSCLC 2020 Update: Is There a Benefit to Short-Course Chemo…
Feat.
G. Riely
